NasdaqCM:MBII

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Marrone Bio Innovations, Inc. discovers, develops, produces, and promotes biological products for pest management, plant nutrition, and plant health in the United States and internationally. More Details


Snowflake Analysis

High growth potential with mediocre balance sheet.


Similar Companies

Share Price & News

How has Marrone Bio Innovations's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MBII is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: MBII's weekly volatility (12%) has been stable over the past year.


Market Performance


7 Day Return

-12.3%

MBII

1.7%

US Chemicals

-0.4%

US Market


1 Year Return

117.5%

MBII

38.9%

US Chemicals

36.2%

US Market

Return vs Industry: MBII exceeded the US Chemicals industry which returned 38.9% over the past year.

Return vs Market: MBII exceeded the US Market which returned 36.2% over the past year.


Shareholder returns

MBIIIndustryMarket
7 Day-12.3%1.7%-0.4%
30 Day-4.7%0.7%-2.9%
90 Day77.8%5.8%5.0%
1 Year117.5%117.5%42.0%38.9%39.1%36.2%
3 Year26.6%26.6%27.3%7.6%48.4%39.0%
5 Year94.8%94.8%92.2%53.6%116.5%92.4%

Long-Term Price Volatility Vs. Market

How volatile is Marrone Bio Innovations's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Marrone Bio Innovations undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: MBII ($2.24) is trading below our estimate of fair value ($6.22)

Significantly Below Fair Value: MBII is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: MBII is unprofitable, so we can't compare its PE Ratio to the US Chemicals industry average.

PE vs Market: MBII is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MBII's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MBII is overvalued based on its PB Ratio (14.8x) compared to the US Chemicals industry average (2.6x).


Next Steps

Future Growth

How is Marrone Bio Innovations forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

59.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MBII is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: MBII is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: MBII's is expected to become profitable in the next 3 years.

Revenue vs Market: MBII's revenue (27.2% per year) is forecast to grow faster than the US market (10% per year).

High Growth Revenue: MBII's revenue (27.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if MBII's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Marrone Bio Innovations performed over the past 5 years?

7.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MBII is currently unprofitable.

Growing Profit Margin: MBII is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MBII is unprofitable, but has reduced losses over the past 5 years at a rate of 7.5% per year.

Accelerating Growth: Unable to compare MBII's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MBII is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-1.4%).


Return on Equity

High ROE: MBII has a negative Return on Equity (-112.95%), as it is currently unprofitable.


Next Steps

Financial Health

How is Marrone Bio Innovations's financial position?


Financial Position Analysis

Short Term Liabilities: MBII's short term assets ($24.0M) exceed its short term liabilities ($22.9M).

Long Term Liabilities: MBII's short term assets ($24.0M) do not cover its long term liabilities ($26.0M).


Debt to Equity History and Analysis

Debt Level: MBII's debt to equity ratio (108.2%) is considered high.

Reducing Debt: MBII's debt to equity ratio has reduced from 734.5% to 108.2% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MBII has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: MBII has sufficient cash runway for 1 years if free cash flow continues to grow at historical rates of 18.8% each year.


Next Steps

Dividend

What is Marrone Bio Innovations's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MBII's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MBII's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MBII's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MBII's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MBII's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Kevin Helash (55 yo)

0.58

Tenure

Mr. Kevin R. Helash serves as Chief Executive Officer and Director at Marrone Bio Innovations, Inc. since August 03, 2020. He had been the Chief Executive Officer of Agrinos AS since November 20, 2017 unti...


Leadership Team

NamePositionTenureCompensationOwnership
Pamela Marrone
Founder15.17yrsUS$894.20k1.39%
$ 5.2m
Kevin Hammill
Chief Manufacturing Officer2.83yrsUS$701.20k0.023%
$ 85.9k
Kevin Helash
CEO & Director0.58yrno datano data
Suping Cheung
Chief Financial Officer0.083yrno datano data
Amit Vasavada
Senior VP of R&D and Chief Technical Officer4.58yrsno datano data
Clyde Montevirgin
Vice President of Business Development & Investor Relationsno datano datano data
Linda Moore
Executive VP & General Counsel7yrsUS$443.38kno data
Andre Trepanier
Director of Marketingno datano datano data
Barner Jones
Director of National Sales & Account Management2.42yrsno datano data
Keith Pitts
Senior VP of Regulatory & Government Affairs and Chief Sustainability Officer4.58yrsno datano data
Matti Tiainen
Senior Vice President of International Sales0.083yrno data0.0028%
$ 10.5k

2.8yrs

Average Tenure

56yo

Average Age

Experienced Management: MBII's management team is considered experienced (2.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Pamela Marrone
Founder15.17yrsUS$894.20k1.39%
$ 5.2m
Kevin Helash
CEO & Director0.58yrno datano data
Stuart Woolf
Independent Director2.58yrsUS$75.02kno data
Robert Woods
Independent Chairman3.08yrsUS$119.30k0.0021%
$ 7.8k
William Fenical
International Science Advisory Panel Memberno datano datano data
Zachary Wochok
Independent Director4.83yrsUS$90.80k0.029%
$ 109.3k
Roberta Farrell
International Science Advisory Panel Memberno datano datano data
Gabriele Berg
International Science Advisory Panel Memberno datano datano data
Trevor Jackson
International Science Advisory Panel Memberno datano datano data
Henk Noorman
International Science Advisory Panel Memberno datano datano data
Orlando Rojas
International Science Advisory Panel Memberno datano datano data
Keith McGovern
Independent Director2.58yrsUS$75.02kno data

2.8yrs

Average Tenure

62yo

Average Age

Experienced Board: MBII's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 25.5%.


Top Shareholders

Company Information

Marrone Bio Innovations, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Marrone Bio Innovations, Inc.
  • Ticker: MBII
  • Exchange: NasdaqCM
  • Founded: 2006
  • Industry: Fertilizers and Agricultural Chemicals
  • Sector: Materials
  • Market Cap: US$375.151m
  • Shares outstanding: 167.48m
  • Website: https://www.marronebio.com

Number of Employees


Location

  • Marrone Bio Innovations, Inc.
  • 1540 Drew Avenue
  • Davis
  • California
  • 95618
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MBIINasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDAug 2013
0MBDB (Deutsche Boerse AG)YesCommon StockDEEURAug 2013

Biography

Marrone Bio Innovations, Inc. discovers, develops, produces, and promotes biological products for pest management, plant nutrition, and plant health in the United States and internationally. Its products i...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/03/08 00:20
End of Day Share Price2021/03/05 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.